| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/13/2010 | CA2336807C Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 04/13/2010 | CA2295678C Pyridine derivatives |
| 04/08/2010 | WO2010039947A1 Novel compounds as calcium channel blockers |
| 04/08/2010 | WO2010039647A2 Selective inhibitors of c-jun n-terminal kinases |
| 04/08/2010 | WO2010039186A2 Compounds useful as faah modulators and uses thereof |
| 04/08/2010 | WO2010038965A2 GCH1-TARGETED si RNA, RECOMBINANT VECTOR CONTAINING si RNA, AND PHARMACEUTICAL COMPOSITION CONTAINING RECOMBINANT VECTOR FOR TREATING AND PREVENTING NEUROPATHIC PAIN |
| 04/08/2010 | WO2010038948A2 Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders |
| 04/08/2010 | WO2010038901A1 7-piperidinoalkyl-3,4-dihydroquinolone derivative |
| 04/08/2010 | WO2010038803A1 2-indoleacrylamide analogue |
| 04/08/2010 | WO2010038771A1 Light-stabilized pharmaceutical composition |
| 04/08/2010 | WO2010038686A1 Novel fused aminodihydrothiazine derivative |
| 04/08/2010 | WO2010038434A1 Process for production of optically active hexahydropyrroloquinoline and intermediate for the process |
| 04/08/2010 | WO2010038200A1 Oxazolidine compounds as orexin receptor antagonists |
| 04/08/2010 | WO2010038167A1 Oxopiperidinyl and pyranyl sulfonamides as ampa potentiators |
| 04/08/2010 | WO2010037884A1 In vitro cellular composition with simultaneous overexpression of mutated human genes ps1m146v, appswe and taup301l |
| 04/08/2010 | WO2010037841A1 Treatment of mood and anxiety disorders |
| 04/08/2010 | WO2010037760A1 Compounds which potentiate ampa receptor and uses thereof in medicine |
| 04/08/2010 | WO2010037723A1 Compounds which have activity at m1 receptor and their uses in medicine |
| 04/08/2010 | WO2010037536A1 N-protected guanidine-substituted furans, thiophenes, and pyrrols as cysteine protease inhibitors |
| 04/08/2010 | WO2010037398A1 Oral formulation |
| 04/08/2010 | WO2010037257A1 New benzazepine compounds, preparation methods and uses thereof |
| 04/08/2010 | WO2010018231A3 Salt of, and processes for the preparation of, 1-isopropyl-4-{[4-(tetrahydro-2h-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1h-1,4-diazepine |
| 04/08/2010 | WO2009156092A3 Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors |
| 04/08/2010 | WO2009155488A3 Novel oxalate salt and crystal of o-desmethylvenlafaxine |
| 04/08/2010 | WO2009101458A3 New polymorph and amorphous forms of desvenlafaxine fumarate |
| 04/08/2010 | US20100088778 Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene |
| 04/08/2010 | US20100087795 Self-learning drug delivery system |
| 04/08/2010 | US20100087536 Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof |
| 04/08/2010 | US20100087527 Curcumin Derivatives |
| 04/08/2010 | US20100087525 Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester |
| 04/08/2010 | US20100087521 Biologically active complex |
| 04/08/2010 | US20100087518 Delta 9 - tetrahydrocannabinol processing |
| 04/08/2010 | US20100087504 Use of Diindolylmethane (DIM) Compounds and Derivatives as Neuroprotective Agents |
| 04/08/2010 | US20100087502 Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders |
| 04/08/2010 | US20100087487 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| 04/08/2010 | US20100087480 Substituted phenylmethyl bicyclocarboxyamide compounds |
| 04/08/2010 | US20100087477 Selective glycosidase inhibitors |
| 04/08/2010 | US20100087475 Pharmaceutical compounds |
| 04/08/2010 | US20100087470 Buprenorphine-Wafer for Drug Substitution Therapy |
| 04/08/2010 | US20100087455 Substituted xanthine compounds |
| 04/08/2010 | US20100087453 Compounds, screens, and methods of treatment |
| 04/08/2010 | US20100087451 Polymorph b of n--n-methyl-acetamide |
| 04/08/2010 | US20100087450 Organic compounds |
| 04/08/2010 | US20100087449 Heteroarylamide pyrimidone compounds |
| 04/08/2010 | US20100087446 2-substituted indole derivatives as calcium channel blockers |
| 04/08/2010 | US20100087445 Aryl piperazine derivatives useful for the treatment of neuropsychiatry disorders |
| 04/08/2010 | US20100087439 Novel preventive and/or therapeutic agent for neuropathic pain |
| 04/08/2010 | US20100087433 Methods of inhibiting tryptophan hydroxylase |
| 04/08/2010 | US20100087429 Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use |
| 04/08/2010 | US20100087426 Process and intermediates for the synthesis of 8-[-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds |
| 04/08/2010 | US20100087425 Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors |
| 04/08/2010 | US20100087423 New benzamide derivatives as bradykinin antagonists |
| 04/08/2010 | US20100087422 Treatment of adhd |
| 04/08/2010 | US20100087421 Method to determine the risk for side effects of an ssri treatment in a person |
| 04/08/2010 | US20100087411 Substituted sapogenins and their use |
| 04/08/2010 | US20100087400 Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof |
| 04/08/2010 | US20100087396 Novel Compounds Having Selective Inhibiting Effect at GSK3 |
| 04/08/2010 | US20100087383 Intracerebral oxidation inhibitor and use thereof |
| 04/08/2010 | US20100087375 Modulation of synaptogenesis |
| 04/08/2010 | US20100087366 Gh secretagogues and uses thereof |
| 04/08/2010 | US20100087365 Pharmaceutical Compositions of Hglp-1, Exendin-4 and Analogs Thereof |
| 04/08/2010 | US20100086972 Process for the production of biodegradable, functionalised polymer particles and use thereof as pharmaceutical supports |
| 04/08/2010 | US20100086582 Amorphous rotigotine transdermal system |
| 04/08/2010 | US20100086565 Vectors for expression of hml-2 polypeptides |
| 04/08/2010 | US20100086558 isolated from Coprinus clastophyllus; for treating celiac disease caused by proline abundant gluten |
| 04/08/2010 | US20100086545 Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| 04/08/2010 | US20100086542 Potentiation of erythropoietin (epo) action by membrane steroid receptor agonists |
| 04/08/2010 | DE102007010077B4 [1,3]-Dioxane zur Modulation von GABAa-Rezeptoren [1,3] -Dioxane for modulation of GABAa receptors |
| 04/08/2010 | CA2739513A1 7-piperidinoalkyl-3,4-dihydroquinolone derivative |
| 04/08/2010 | CA2738323A1 Treatment of mood and anxiety disorders |
| 04/08/2010 | CA2738150A1 Novel fused aminodihydrothiazine derivative |
| 04/08/2010 | CA2738041A1 Oxopiperidinyl and pyranyl sulfonamides as ampa potentiators |
| 04/08/2010 | CA2737480A1 Novel compounds as calcium channel blockers |
| 04/08/2010 | CA2732613A1 Oral formulation |
| 04/07/2010 | EP2172478A2 Activity-dependent neurotrophic factor III (ADNF III) |
| 04/07/2010 | EP2172469A1 Diazabicyclic aryl derivatives as cholinergic receptor modulators |
| 04/07/2010 | EP2172468A1 Benzimidazolone compounds |
| 04/07/2010 | EP2172460A1 Compositions useful as inhibitors of JAK and other protein kinases |
| 04/07/2010 | EP2172457A2 Fredericamycin derivatives |
| 04/07/2010 | EP2172453A1 COMPOUND HAVING 11 ß-HSD1 INHIBITORY ACTIVITY |
| 04/07/2010 | EP2172444A1 Pet probe having alkoxy group substituted by fluorine and hydroxy group |
| 04/07/2010 | EP2172246A2 Methods for Alzheimer's disease treatment and cognitive enhancement |
| 04/07/2010 | EP2172217A1 Fibrosis inhibitor |
| 04/07/2010 | EP2172209A1 Treatment of mood and anxiety disorders |
| 04/07/2010 | EP2172206A1 The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof |
| 04/07/2010 | EP2172199A1 Sustained release tablet comprising pramipexole |
| 04/07/2010 | EP2172197A1 Octanoic acid derivative to treat fibromyalgia and other pains |
| 04/07/2010 | EP2172115A1 Composition for use in the reduction of blood alcohol content |
| 04/07/2010 | EP2170953A1 Monoclonal anti beta amyloid antibody |
| 04/07/2010 | EP2170920A1 Stable salts of s-adenosylmethionine and process for the preparation thereof |
| 04/07/2010 | EP2170903A1 Spiro ýpiperidine-4, 4' -thieno ý3, 2-c¨pyran¨derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| 04/07/2010 | EP2170896A2 Polycyclic guanine derivatives and use thereof |
| 04/07/2010 | EP2170875A1 Aminoalkylazole derivatives as histamine-3 antagonists |
| 04/07/2010 | EP2170861A2 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| 04/07/2010 | EP2170824A1 Novel process |
| 04/07/2010 | EP2170816A1 N-oxides of venlafaxine and o-desmethylvenlafaxine as prodrugs |
| 04/07/2010 | EP2170809A2 Methods for the preparation and formulation of l-carnitine valproate salts |
| 04/07/2010 | EP2170807A1 Spiro compounds useful as antagonists of the h1 receptor |
| 04/07/2010 | EP2170401A1 Dendrimer conjugates of agonists and antagonists of the gpcr superfamily |
| 04/07/2010 | EP2170389A1 Humanized antibodies to amyloid beta |